M
Myricx Bio
Biotech & Life Sciences · London, United Kingdom · Founded 2019
Novel antibody-drug conjugate payloads for cancer treatment MoreLess
Myricx Bio is a UK-based biotechnology company specializing in the discovery and development of a new class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). These ADCs are based on inhibitors of the enzyme NMT (N-myristoyltransferase) and are designed to treat various types of cancer. The company operates in the biopharmaceutical market, targeting oncology therapeutics. Myricx Bio serves pharmaceutical companies and research institutions looking for advanced cancer treatment solutions. The business model revolves around research and development, followed by licensing agreements and partnerships with larger pharmaceutical firms to bring their innovations to market. Revenue is generated through these partnerships, licensing deals, and potentially future sales of developed therapies.
Keywords: biotechnology, ADCs, NMT inhibitors, cancer treatment, oncology, cytotoxic payloads, drug development, licensing, partnerships, UK-based.
Company overview
Myricx Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2019
- Headquarters
- London, United Kingdom
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 90.8
Valuation & funding
Myricx Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2024 | $119M | $475M | Sofinnova Partners · Brandon Capital Partners · British Patient Capital · Abingworth | ↗ |
| SEEDOther financing | Nov 2020 | $5.9M | $24M | Brandon Capital Partners · Sofinnova Partners | — |
| SPINOUTOther financing | Dec 2019 | $0 | — | College of Medicine and Integrated Health | — |
| SPINOUTOther financing | Jul 2019 | $0 | — | Imperial College London | — |
Growth signals
Myricx Bio website traffic
Latest recorded traffic for Myricx Bio is 660 monthly website visits, up 371.4% over the last three months. Myricx Bio's team grew 16.1% over the past year.
Comparisons
Myricx Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Myricx Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Myricx Bio has talent and traffic
team presence
In the news
Latest news about Myricx Bio
Recent press, funding announcements, and product moves mentioning Myricx Bio — open to read from the original sources.
Market sentiment
What the market is saying about Myricx Bio
An AI-synthesized read of the highest-engagement posts about Myricx Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myricx Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.